Patents Represented by Attorney Hueschen and Sage

Find this attorney in the Justia Lawyer Directory

  • Therapeutic composition comprising a botulinum neurotoxin
    Patent number: 7964199
    Abstract: A pharmaceutical preparation comprising one of the botulinum neurotoxins from Clostridium botulinum of types A, B, C, D, E, F or G or a mixture of two or more of these neurotoxins, wherein the neurotoxin or the mixture of neurotoxins is free of the complexing proteins which naturally form the botulinum neurotoxin complexes together with the neurotoxins.
    Type: Grant
    Filed: May 26, 2000
    Date of Patent: June 21, 2011
    Assignee: MERZ PHARMA GmbH & Co. KGaA
    Inventors: Hans Bigalke, Jürgen Frevert
  • Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
    Patent number: 7960438
    Abstract: The present invention relates to the use of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, in obtaining medicaments intended for the treatment of Generalized Anxiety Disorder.
    Type: Grant
    Filed: April 4, 2007
    Date of Patent: June 14, 2011
    Assignee: Les Laboratoires Servier
    Inventors: Bruno Delalleau, Agnes Fabiano, Mark Millan, Elisabeth Mocaer
  • Naphthalene compounds, a process for their preparation and pharmaceutical compositions containing them
    Patent number: 7947852
    Abstract: Compounds of formula (I): wherein: R1 represents alkyl, alkenyl, haloalkyl, polyhaloalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, X represents a group N—OR2 wherein R2 represents a hydrogen atom or an alkyl group. Medicinal products containing the same which are useful in treating disorders of the melatoninergic system.
    Type: Grant
    Filed: July 1, 2008
    Date of Patent: May 24, 2011
    Assignee: Les Laboratoires Servier
    Inventors: Said Yous, Mohamed Ettaoussi, Ahmed Sabaouni, Pascal Berthelot, Michael Spedding, Philippe Delagrange, Daniel-Henri Caignard, Mark Millan
  • Substituted pyrazolo[1,5-a]pyrimidines as metabotropic glutamate receptor modulators
    Patent number: 7947689
    Abstract: The invention relates to pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2 and Y3 independently are e.g. CR10, NH, S or O, whereby at least one of Y1, Y2 and Y3 represents CR10; R1 represents chloro or bromo; R2, R3, R4, R5, R6 and R7 represent e.g. hydrogen or C1-C6-alkyl, and R10 represents e.g. hydrogen, halogen or phenyl; which are potent mGluR5 modulators and are e.g. useful for the treatment of various neurological disorders.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: May 24, 2011
    Assignee: Merz Pharma GmbH & Co. KGaA
    Inventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Graham Raphael Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaits, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
  • Use of agomelatine in obtaining medicaments intended for the treatment of bipolar disorders
    Patent number: 7947743
    Abstract: The present invention relates to the use of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, on its own or in association, in obtaining medicaments intended for the treatment of bipolar disorders, especially bipolar disorders of types I and II, and more especially bipolar disorders of type I.
    Type: Grant
    Filed: June 1, 2005
    Date of Patent: May 24, 2011
    Assignee: Les Laboratories Servier
    Inventors: Christian De Bodinat, Elisabeth Mocaer
  • Crystalline form III of agomelatine, a process for its preparation and pharmaceutical compositions containing it
    Patent number: 7939566
    Abstract: Crystalline form III of the compound of formula (I): characterised by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful in the treatment of melatoninergic disorders.
    Type: Grant
    Filed: November 10, 2009
    Date of Patent: May 10, 2011
    Assignee: Les Laboratoires Servier
    Inventors: Gerard Coquerel, Julie Linol, Jean-Claude Souvie
  • Process for the synthesis of 7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
    Patent number: 7928223
    Abstract: Process for the synthesis of the compound of formula (I): Application in the synthesis of ivabradine, addition salts thereof with a pharmaceutically acceptable acid and hydrates thereof.
    Type: Grant
    Filed: June 17, 2009
    Date of Patent: April 19, 2011
    Assignee: Les Laboratoires Servier
    Inventors: Jean-Michel Lerestif, Jean-Pierre Lecouve, Daniel Brigot
  • Device and method for the production of biologically active compounds by fermentation
    Patent number: 7927836
    Abstract: The present invention relates to a process and an apparatus for the fermentational production of biologically active materials, wherein a fermenter is located in an insulator which, in turn, is located within a working chamber or is adjacent to it. A pressure gradient in relation to ambient pressure prevails in both the insulator and in the working chamber.
    Type: Grant
    Filed: December 13, 2007
    Date of Patent: April 19, 2011
    Assignee: Merz Pharma GmbH & Co. KGaA
    Inventors: Bernd Doelle, Michael Pfeil
  • Peptides which interact with anti-apoptotic members of the Bcl-2 protein family, and uses
    Patent number: 7927813
    Abstract: The invention relates to a method of screening and identifying modulators of the protein interaction between new peptides and anti-apoptotic members of the Bcl-2 protein family. The modulators identified on the basis of this method are administered to patients with cancer in order to bring about apoptotic-type and/or autophagic-type programmed cell death in those patients.
    Type: Grant
    Filed: January 31, 2006
    Date of Patent: April 19, 2011
    Assignees: Les Laboratories Servier, Hybrigenics
    Inventors: Olivier Geneste, John Hickman, Jean-Christophe Rain
  • ? Crystalline form of the arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it
    Patent number: 7923569
    Abstract: ?-crystalline form of the compound of formula (I): characterised by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful as inhibitors of angiotensin I converting enzyme.
    Type: Grant
    Filed: February 26, 2007
    Date of Patent: April 12, 2011
    Assignee: Les Laboratoires Servier
    Inventors: Gérard Coquerel, Loïc Lefebvre, Jean-Claude Souvie, Pascale Authouart
  • Motif of the beclin protein which interacts with anti-apoptotic members of the Bcl-2 protein family, and uses
    Patent number: 7919233
    Abstract: The invention relates to a method of identifying modulators of programmed cell death, comprising an interaction between a motif of Beclin protein and an anti-apoptotic member of the family of Bcl-2 proteins and the detection of said interaction be means of fluorescence polarization. The modulators identified on the basis of said method are administered to cancer patients in order to induce apoptotic- and/or autophagic-type programmed cell death. The invention also relates to a motif of the Beclin protein which can interact with an anti-apoptic member of the family of Bcl-2 proteins and to the use thereof in order to induce programmed cell death in a cancer patient.
    Type: Grant
    Filed: January 31, 2006
    Date of Patent: April 5, 2011
    Assignee: Les Laboratoires Servier
    Inventors: Olivier Geneste, John Hickman, Jean-Christophe Rain
  • Crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it
    Patent number: 7910625
    Abstract: Crystalline form IV of the compound of formula (I): characterised by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful in the treatment of melatoninergic disorders.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: March 22, 2011
    Assignee: Les Laboratoires Servier
    Inventors: Gerard Coquerel, Julie Linol, Jean-Claude Souvie
  • Azabicylic compounds, a process for their preparation and pharmaceutical compositions containing them
    Patent number: 7906547
    Abstract: Compounds of formula (I): wherein: ALK represents an alkylene chain, W represents a group selected from wherein R and R? are as defined in the description. Medicinal products containing the same which are useful in the treatment of cognitive and psycho-behavioural disorders associated with cerebral ageing, with neurodegenerative diseases or with cranial traumas and also in the treatment of mood disorders, of schizophrenia and of cognitive disorders associated therewith, of sleep disorders, of sleep-waking rhythm disorders, of attention-deficit hyperactivity syndrome or of obesity.
    Type: Grant
    Filed: June 12, 2009
    Date of Patent: March 15, 2011
    Assignee: Les Laboratoires Servier
    Inventors: Patrick Casara, Anne-Marie Chollet, Alain Dhainaut, Pierre Lestage, Fany Panayi, Anita Roger
  • Association between agomelatine and a thymoregulatory agent and pharmaceutical compositions containing it
    Patent number: 7902180
    Abstract: Association comprising agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, in association with a thymoregulatory agent. Medicinal products containing the same which are useful in the treatment of mood disorders.
    Type: Grant
    Filed: September 7, 2006
    Date of Patent: March 8, 2011
    Assignee: Les Laboratoires Servier
    Inventor: Christian De Bodinat
  • Method for preparing medetomidine and its salts
    Patent number: 7902377
    Abstract: The invention provides an improved, highly efficient method for preparing Medetomidine, and its salts, in particular its pharmaceutically acceptable salts. The method utilizes the high reactivity of halogenated imidazoles towards transmetalation with Grignard reagents and the subsequent reaction with 2,3-dimethylbenzaldehyde.
    Type: Grant
    Filed: November 2, 2007
    Date of Patent: March 8, 2011
    Assignee: JSC Grindeks
    Inventors: Inese Reine, Armands Zandersons
  • Orodispersible pharmaceutical composition for oromucosal or sublingual administration of agomelatine
    Patent number: 7892575
    Abstract: The invention relates to a coated solid orodispersible pharmaceutical composition for the administration of agomelatine by the oral, oromucosal or sublingual route.
    Type: Grant
    Filed: December 14, 2006
    Date of Patent: February 22, 2011
    Assignee: Les Laboratoires Servier
    Inventors: Mark Julien, Jean-Manuel Pean, Francois Tharrault, Patrick Wuthrich
  • Delta D-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
    Patent number: 7879841
    Abstract: A ?d-crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.
    Type: Grant
    Filed: August 27, 2009
    Date of Patent: February 1, 2011
    Assignee: Les Laboratoires Servier
    Inventors: Stephane Horvath, Marie-Noelle Auguste, Gerard Damien
  • Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
    Patent number: 7879842
    Abstract: ?-Crystalline form of ivabradine of formula (I): characterised by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful as bradycardics.
    Type: Grant
    Filed: October 21, 2009
    Date of Patent: February 1, 2011
    Assignee: Les Laboratoires Servier
    Inventors: Stephane Horvath, Marie-Noelle Auguste, Gerard Damien
  • Therapeutic composition with a botulinum neurotoxin
    Patent number: 7879341
    Abstract: The present invention pertains to pharmaceutical compositions which comprise a botulinum neurotoxin from Clostridium botulinum, the neurotoxin being free of the complexing proteins naturally present in the botulinum neurotoxin complex or being chemically modified or being modified by genetic manipulation. Moreover the pharmaceutical compositions of the instant invention have good stability and are advantageously formulated free of human serum albumin.
    Type: Grant
    Filed: July 19, 2005
    Date of Patent: February 1, 2011
    Assignee: MERZ PHARMA GmbH & Co. KGaA
    Inventor: Harold Victor Taylor
  • Gamma d-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
    Patent number: 7872001
    Abstract: A ?d-Crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.
    Type: Grant
    Filed: August 27, 2009
    Date of Patent: January 18, 2011
    Assignee: Les Laboratoires Servier
    Inventors: Stephane Horvath, Marie-Noelle Auguste, Gerard Damien